Close Menu

NEW YORK – ARUP Laboratories said on Thursday that the US Food and Drug Administration has accepted its premarket approval submission for an AAV5 total antibody assay intended as a companion diagnostic for an investigational severe hemophilia gene therapy treatment being developed by BioMarin Pharmaceutical.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.